Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>

Benzinga

2025/11/04

Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma. The CRISPR genome-...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2580924345"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580924345\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580924345?lang=zh_CN&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/03/Gene-editing.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2025-11-04 00:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580924345","market":"nz","top_or_hot":-1,"title":"Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>","media":"Benzinga","content":"<div>\n<p>Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.\nThe CRISPR genome-...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/25/11/48596655/why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today\">网页链接</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-04 00:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/fda/25/11/48596655/why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.\nThe CRISPR genome-...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/25/11/48596655/why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/news/fda/25/11/48596655/why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today","article_id":"2580924345","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/03/Gene-editing.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/fda/25/11/48596655/why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2580924345","pubTimestamp":1762188480,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Caribou Biosciences Inc.  stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.The CRISPR genome-editing biopharmaceutical company shared preliminary results from its ongoing ANTLER phase 1 trial of vispacabtagene regedleucel , an allogeneic anti-CD19 CAR-T cell therapy, for relapsed or refractory B-cell non-Hodgkin lymphoma.The cell therapy uses T-cells from a healthy donor, rather than the patient's own cells, to fight cancer.Also Read: FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering. In the study, 64% of patients treated with Caribou's therapy achieved a complete response. The overall response rate was 82%.In recent interactions, the FDA has recommended that the company conduct a randomized, controlled trial in second-line  large B-cell lymphoma  CD19-naive patients who are ineligible for transplant and autologous CAR-T cell therapy.The company is advancin","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CRSP":"CRISPR Therapeutics AG","BK4611":"AI医疗","BK4585":"ETF&股票定投概念","CAR":"安飞士","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4230":"旅客陆运","LU1861558580.USD":"日兴方舟颠覆性创新基金B","CRBU":"Caribou Biosciences","BK4588":"碎股","BK4022":"陆运","BK4539":"次新股","BK4556":"基因编辑"},"translate_title":"为什么CRISPR基因组编辑公司Caribou Biosciences股票今天交易走高>","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1.5,"CAR":0.63,"CRBU":1.5},"content_text":"Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.\nThe CRISPR genome-editing biopharmaceutical company shared preliminary results from its ongoing ANTLER phase 1 trial of vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy, for relapsed or refractory B-cell non-Hodgkin lymphoma.\nThe cell therapy uses T-cells from a healthy donor, rather than the patient's own cells, to fight cancer.\nAlso Read: FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering\nIn the study, 64% of patients treated with Caribou's therapy achieved a complete response. The overall response rate was 82%.\nAt one year, progression-free survival was 51% (patients remain alive without their cancer worsening).\nCaribou said data from this 35-patient cohort further confirmed that the efficacy and durability of vispa-cel are on par with the autologous CAR-T cell therapies.\nIn all patients treated in ANTLER (N=84), vispa-cel has demonstrated a generally well-tolerated safety profile.\nIn recent interactions, the FDA has recommended that the company conduct a randomized, controlled trial in second-line (2L) large B-cell lymphoma (LBCL) CD19-naive patients who are ineligible for transplant and autologous CAR-T cell therapy.\nThe company intends to follow this approach with its planned pivotal phase 3 trial design, evaluating approximately 250 patients.\nSeparately, Caribou shared the first clinical data from the dose escalation phase of the ongoing CaMMouflage Phase 1 trial of CB-011, an off-the-shelf anti-BCMA CAR-T cell therapy, in patients with relapsed or refractory multiple myeloma.\nThe company is advancing the program into dose expansion, which it expects to initiate by the end of this year, and it plans to share dose expansion data in 2026.\nOverall response rate was 92%, and complete response rate was 75%. 91% of the patients achieved minimal residual disease (MRD) negativity (no cancer cells were detected).\nCB-011 had a manageable safety profile across all dose levels and lymphodepletion regimens (N=48).\nPrice Action: CRBU stock is up 17.56% at $2.84 at the last check on Monday.\nRead Next:\nPhoto via Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}